US2004142869A1PendingUtilityA1
Methods of use of recombinant vasoactive protein from salivary gland of the black fly
Est. expiryMar 13, 2017(expired)· nominal 20-yr term from priority
A61K 38/00C07K 14/43577
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention is drawn to vasodilative proteins from the salivary glands of the species, Simulium . The protein additionally has immunomodulating activities. Methods for recombinant production of the protein as well as biomedical uses are provided.
Claims
exact text as granted — not AI-modifiedThat which is claimed is:
1 . A method for treating a wound in a mammal, said method comprising administering a therapeutically effective amount of a protein comprising an amino acid sequence which is at least 90% identical to the mature form of the amino acid sequence of SEQ ID NO:2, wherein said protein promotes wound healing.
2 . The method of claim 1 , wherein said protein comprises an amino acid sequence which is at least 95% identical to the mature form of the amino acid sequence of SEQ ID NO:2.
3 . The method of claim 2 , wherein said protein is produced by recombinant methods.
4 . The method of claim 1 , wherein said protein comprises an amino acid sequence which is the mature form of the amino acid of SEQ ID NO:2.
5 . The method of claim 1 , wherein said mammal is a human patient.
6 . The method of claim 5 , wherein said human patient has undergone surgery and said wound is a surgical wound.
7 . The method of claim 6 , wherein said wound is a result of heart failure.
8 . The method of claim 1 , wherein said protein is administered by intradermal injection.
9 . The method of claim 1 , wherein said protein is administered topically.
10 . A method for decreasing inflammation, said method comprising administering a therapeutically effective amount of a protein comprising an amino acid sequence set forth in SEQ ID NO:2, wherein said protein decreases inflammation.Join the waitlist — get patent alerts
Track US2004142869A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.